Process Development and Large-scale GMP Production for Lentiviral Vectors

[WEBINAR] Case Study: Process Development and Large-scale GMP Production for Lentiviral Vectors

How efficient are your lentiviral vector large-scale production and purification processes?
MolMed offers in-house proprietary processes for lentiviral (LV) vector production at large scale. As the evolution of the well-established GMP 48L CF process MolMed is developing a robust and scalable process for the industrial-scale production of both LV vectors for use in gene-modified cell therapy using a scalable platform that includes the iCELLis bioreactor vector production and a downstream purification platform that includes chromatography and TFF steps.

You'll be presented with productivity and quality data obtained with the CF process and the development and optimisation of the LV production process in a bioreactor.

MolMed is a biotechnology company focused on research, development and manufacturing of innovative therapies to treat cancer and rare genetic diseases.
 
Phacilitate webinar with Beckman Coulter - managing cell culture
During this webinar, you will learn:
  • How to perform an efficient LV vector large-scale production and purification processes
  • Process development and large-scale production process using the iCELLis platform
  • How to design an industrial scale viral vector production from bulk production to final filled product

  DETAILS
Date: June 11th 2020
Time: 4pm BST | 11am EST | 8am PST
How: register here


SPEAKERS
Prof Francesco Dazzi, KCL, Phacilitate webinar

Luca Alberici, MBA, CBO, MolMed S.p.a.






Steven Thompson, Sexton Biotechnologies Phacilitate webinar
Margherita Neri, Up-stream Process Development Manager, MolMed S.p.a.






Francesca Bellintani, Down-stream Process Development Manager, MolMed S.p.a.






The webinar will be available on-demand so if you can't make the live session, register your details and we'll send you the recording.